Robin’s experience brings a strong commercial perspective to the assessment of global IP portfolios & strategies in the pharmaceutical and medical device sectors.
Robin joined Reddie & Grose in 2019 and is the firm’s first partner to be based permanently in our Munich office. Robin, a British/German national, actually started his career in 2001 with Reddie & Grose in London before deciding, in 2006, to move to Germany to experience life in continental Europe; learn a second language and work in-house for Novartis’ generic pharmaceutical division, Sandoz.
In his 13 years in-house Robin supported all areas of the business; from product development and in-licencing to commercial operations and launch management. Robin also worked on a number of cross divisional projects with colleagues in Novartis’ originator divisions. The nature of the generic business meant that Robin’s work focussed on more contentious matters such as freedom to operate assessments; licence negotiations; oppositions before the European patent office and managing launch & litigation strategies in European and non-European jurisdictions. For 5 years Robin supported Sandoz’ respiratory business which introduced him to the fascinating world of medical devices before he moved to his final role as head of the global small molecule patent team.
Slightly away from patents, Robin’s work often exposed him to topics relating to regulatory data protection which led him to develop a strong interest in the interplay between the laws governing regulatory and patent derived exclusivities.
Robin enjoys snowboarding, cricket and rugby (although his playing days are long behind him) and faces a daily battle trying to convince his two young children to support the slightly less fashionable Norwich City over Bayern Munich.
